Publications

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

AuthID
P-00X-D3K

Author(s)

Wainberg, ZA

Enzinger, PC

Kang, YK

Qin, SK

Yamaguchi, K

Kim, IH

Saeed, A

Oh, SC

Li, J

Turk, HM

[+1]·

Borg, C

Hitre, E

Udrea, AA

Cardellino, GG

Sanchez, RG

Collins, H

Mitra, S

Yang, YS

Catenacci, DVT

Lee, KW

View all authors

Document Type

Article

Year published

2022

Published

in LANCET ONCOLOGY, ISSN: 1470-2045

Volume: 23, Issue: 11, Pages: 1430-1440 (11)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/s1470-2045(22)00603-9

Pubmed: 36244398

Scopus: 2-s2.0-85140889719

Wos: WOS:000886922400038

Source Identifiers

ISSN: 1470-2045

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Show entries

Search:

Name Order	Name	Name Order	Name	Name Order	Name
1	Wainberg, ZA;	2	Enzinger, PC;	3	Kang, YK;
4	Qin, SK;	5	Yamaguchi, K;	6	Kim, IH;
7	Saeed, A;	8	Oh, SC;	9	Li, J;
10	Turk, HM;	11	Teixeira, A;	12	Borg, C;
13	Hitre, E;	14	Udrea, AA;	15	Cardellino, GG;
16	Sanchez, RG;	17	Collins, H;	18	Mitra, S;
19	Yang, YS;	20	Catenacci, DVT;	21	Lee, KW;

Showing 1 to 7 of 7 entries

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Useful Links

Get Help

Federated Authentication (Click on the image)

Bemarituzumab in Patients with Fgfr2B-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (Fight) : a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Useful Links

Get Help